These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 33339226)

  • 1. Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics.
    de Jong LM; Jiskoot W; Swen JJ; Manson ML
    Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33339226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
    Duricová J; Grundmann M
    Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics in Critical Care.
    Cheek D; Howington L
    AACN Adv Crit Care; 2018; 29(1):36-42. PubMed ID: 29496712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing phenoconversion: the Achilles' heel of personalized medicine.
    Shah RR; Smith RL
    Br J Clin Pharmacol; 2015 Feb; 79(2):222-40. PubMed ID: 24913012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
    Shah RR; Smith RL
    Drug Metab Dispos; 2015 Mar; 43(3):400-10. PubMed ID: 25519488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
    Prandota J
    Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.
    Ingelman-Sundberg M
    Trends Pharmacol Sci; 2004 Apr; 25(4):193-200. PubMed ID: 15063083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.
    Rushmore TH; Kong AN
    Curr Drug Metab; 2002 Oct; 3(5):481-90. PubMed ID: 12369894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochromes P450: decision-making tools for personalized therapeutics.
    Murray M; Petrovic N
    Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing relevance of pharmacogenetics of drug metabolism in clinical practice.
    Pillans PI
    Intern Med J; 2001 Nov; 31(8):476-8. PubMed ID: 11720061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities and obstacles in genotypic prediction of cytochrome P450 phenotypes.
    McGraw J; Gerhardt A; Morris TC
    Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):659-661. PubMed ID: 29863909
    [No Abstract]   [Full Text] [Related]  

  • 14. Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.
    Stanke-Labesque F; Gautier-Veyret E; Chhun S; Guilhaumou R;
    Pharmacol Ther; 2020 Nov; 215():107627. PubMed ID: 32659304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
    Gómez-Lechón MJ; Castell JV; Donato MT
    Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of the cytochromes P450.
    Daly AK
    Curr Top Med Chem; 2004; 4(16):1733-44. PubMed ID: 15579105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacogenomics: the quest for individualized therapy].
    López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME
    Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP450 genotype and pharmacogenetic association studies: a critical appraisal.
    Shah RR; Gaedigk A; LLerena A; Eichelbaum M; Stingl J; Smith RL
    Pharmacogenomics; 2016 Feb; 17(3):259-75. PubMed ID: 26780308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
    Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
    Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.